3w
The ADAPT-SC phase 3 study showed SC efgartigimod was noninferior to IV administration in reducing IgG and improving outcomes in gMG. Extension data support durable tolerability and sustained disease control.
-
BRETT NILE3wlove having another mechanism and tool on the arsenal, looks like this will become a mainstay of treatment.
-
JOEL WASHINSKY3wMuscle weakness from an autoimmune mechanism.
-
SACHINKUMAR PANCHAL1moGeneralized myasthenia gravis (gMG) is an autoimmune disease where the body’s immune system makes harmful IgG antibodies that attack the connection between nerves and muscles, causing muscle weakness.